AMVUTTRA (vutrisiran)
E1292060
UNEXPLORED
AMVUTTRA (vutrisiran) is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
All labels observed (2)
| Label | Occurrences |
|---|---|
| vutrisiran | 2 |
| AMVUTTRA (vutrisiran) canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T17871418 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: AMVUTTRA (vutrisiran) Context triple: [Alnylam Pharmaceuticals, Inc., develops, AMVUTTRA (vutrisiran)]
-
A.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
inotersen
Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
-
D.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
E.
AveXis
AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: AMVUTTRA (vutrisiran) Target entity description: AMVUTTRA (vutrisiran) is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
-
A.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
inotersen
Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
-
D.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
E.
AveXis
AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
- F. None of above. chosen
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: AMVUTTRA (vutrisiran)
linked to: AMVUTTRA (vutrisiran)